Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adenosine Clear all
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

NCT02999984
View directory record Official record
Conditions
Severe Combined Immunodeficiency Due to ADA Deficiency
Interventions
Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101), busulfan, PEG-ADA ERT
Genetic · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Days to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 2 Interventional Results available

Intravenous Allopurinol in Heart Failure

NCT00181155
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Nov 4, 2026, 9:18 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Simulation of Adenosine Push Methods for Treatment of SVT Using Agitated Saline Visualized by Ultrasound

NCT04051541
View directory record Official record
Conditions
Supraventricular Tachycardia
Interventions
Agitated saline push
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Nov 4, 2026, 9:18 AM EST
Not listed Phase 3 Interventional

PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation

NCT01672346
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
PVAI followed by adenosine provocation
Procedure
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake

NCT01690884
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Adenosine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 28, 2018 · Synced Nov 4, 2026, 9:18 AM EST
Completed No phase listed Observational

Genetic Causes of Panic Disorder

NCT00083265
View directory record Official record
Conditions
Panic Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Nov 4, 2026, 9:18 AM EST
Terminated Phase 3 Interventional Results available

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

NCT03642132
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by talazoparib maintenance, Chemotherapy + bevacizumab followed by bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

NCT01123772
View directory record Official record
Conditions
Health
Interventions
INO-8875, Placebo control
Drug · Other
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
35 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Nov 4, 2026, 9:18 AM EST
Recruiting Phase 4 Interventional

Adenosine vs Diltiazem for Treatment of SVT in the ED

NCT06993038
View directory record Official record
Conditions
Supraventricular Tachycardia (SVT)
Interventions
adenosine, diltiazem
Drug
Lead sponsor
Anne E. Zepeski
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Nov 4, 2026, 9:18 AM EST
Not yet recruiting Phase 1Phase 2 Interventional

Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury

NCT05217498
View directory record Official record
Conditions
Spinal Cord Injuries, Myelopathy
Interventions
Istradefylline, low oxygen therapy
Drug · Device
Lead sponsor
Randy Trumbower, PT, PhD
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 2 Interventional Results available

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

NCT03098979
View directory record Official record
Conditions
Heart Failure
Interventions
Neladenoson bialanate (BAY1067197), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Nov 4, 2026, 9:18 AM EST
Completed No phase listed Observational

Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital

NCT02948335
View directory record Official record
Conditions
Infection
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Nov 4, 2026, 9:18 AM EST
Completed No phase listed Observational

Study of Value of Cardiac PET Scans With or Without CT Angiography and/or Measurement of Coronary Flow Reserve

NCT00669968
View directory record Official record
Conditions
Chest Pain, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Kettering Health Network
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 2 Interventional Results available

Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation

NCT03032965
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Adenosine, Isoproterenol
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Nov 4, 2026, 9:18 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of HMB, ATP, and HMB Plus ATP on Muscle Mass, Strength, and Power in Resistance Trained Athletes

NCT01508338
View directory record Official record
Conditions
Healthy Experienced Weight Training Males
Interventions
Placebo, HMB, Peak ATP and HMB, ATP
Dietary Supplement
Lead sponsor
Metabolic Technologies Inc.
Industry
Eligibility
18 Years to 30 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 2 Interventional

KW-6002 to Treat Parkinson's Disease

NCT00006337
View directory record Official record
Conditions
Parkinson's Disease
Interventions
KW-6002, IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 4, 2026, 9:18 AM EST
Not listed Phase 1 Interventional

Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation

NCT03072589
View directory record Official record
Conditions
Lung Transplant
Interventions
Regadenoson infusion
Drug
Lead sponsor
Christine Lau, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Nov 4, 2026, 9:18 AM EST
Completed Not applicable Interventional Results available

AMPLATZER Duct Occluder II Additional Sizes

NCT03055858
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
ADO II AS (PDA closure)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
3 Days and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
9
States / cities
Los Angeles, California • Orlando, Florida • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 2 Interventional

A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies

NCT00038025
View directory record Official record
Conditions
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Deoxycoformycin (DCF)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 3 Interventional Results available

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

NCT02264990
View directory record Official record
Conditions
Non-squamous Non-small Cell Lung Cancer
Interventions
Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
25
States / cities
Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 1 Interventional

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

NCT01983501
View directory record Official record
Conditions
HER2 Positive Breast Cancers
Interventions
Tucatinib (ONT-380), T-DM1
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Nov 4, 2026, 9:18 AM EST
Completed Phase 1Phase 2 Interventional Results available

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

NCT01852071
View directory record Official record
Conditions
ADA-SCID
Interventions
Infusion of autologous EFS-ADA LV CD34+ (OTL-101), busulfan, PEG-ADA ERT
Genetic · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
1 Month to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Nov 4, 2026, 9:18 AM EST
Not listed No phase listed Observational

Performance of a New REsting Pressure Index During Invasive Angiography Compared To Adenosine Hyperemic FFR

NCT03237169
View directory record Official record
Conditions
Fractional Flow Reserve, Myocardial, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Centro Hospitalar Lisboa Ocidental
Government
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Nov 4, 2026, 9:18 AM EST